Alnylam Pharmaceuticals (ALNY) Inventory (2018 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Inventory came in at $97.1 million in Q2 2026, up 35.46% YoY from $71.7 million in Q2 2025, and up 15.57% on a QoQ basis from $84.0 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Inventory (2018 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 9 years of Inventory data on file, last reported at $97.1 million in Q2 2026.
- Quarterly Inventory rose 35.46% year-over-year to $97.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $97.1 million (up 35.46% YoY) and the FY2025 annual result came in at $82.7 million, up 5.36% from the prior year.
- Inventory grew to $97.1 million in Q2 2026, from $84.0 million in the prior quarter.
- In the past five years, Inventory ranged from a high of $131.9 million in Q1 2023 to a low of $65.6 million in Q1 2025.
- A 5-year average of $91.0 million and a median of $86.5 million in 2022 frame the typical range for Inventory.
- The widest YoY moves for Inventory: up 67.96% in 2023, down 30.87% in 2023.
- Tracing ALNY's Inventory over 5 years: stood at $129.0 million in 2022, then sank by 30.87% to $89.1 million in 2023, then decreased by 11.93% to $78.5 million in 2024, then increased by 5.36% to $82.7 million in 2025, then climbed by 17.4% to $97.1 million in 2026.
- The last three Inventory figures came in at $97.1 million (Q2 2026), $84.0 million (Q1 2026), and $82.7 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.77 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.08 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 371.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 732.60 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 358,916.96 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 97.11 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 142.38 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.11 Mn |
| Mar 31, 2026 | 84.03 Mn |
| Dec 31, 2025 | 82.72 Mn |
| Sep 30, 2025 | 75.38 Mn |
| Jun 30, 2025 | 71.69 Mn |
| Mar 31, 2025 | 65.58 Mn |
| Dec 31, 2024 | 78.51 Mn |
| Sep 30, 2024 | 75.99 Mn |
| Jun 30, 2024 | 83.98 Mn |
| Mar 31, 2024 | 93.99 Mn |
| Dec 31, 2023 | 89.15 Mn |
| Sep 30, 2023 | 95.77 Mn |
| Jun 30, 2023 | 100.45 Mn |
| Mar 31, 2023 | 131.88 Mn |
| Dec 31, 2022 | 128.96 Mn |
| Sep 30, 2022 | 115.49 Mn |
| Jun 30, 2022 | 88.98 Mn |
| Mar 31, 2022 | 78.52 Mn |
| Dec 31, 2021 | 86.36 Mn |
| Sep 30, 2021 | 97.90 Mn |